Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!
CMC Strategy for Novel AAV Capsids
PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES
CMC Strategy for Novel AAV Capsids
CMC Strategy for Novel AAV Capsids: From Vector Engineering to IND Filing
CELL & GENE | RNA | BIOLOGICS
Proven Intelligence in AAV Vector Engineering and Analytics.
Executive Summary
Developing a Chemistry, Manufacturing, and Controls (CMC) strategy for a novel adeno-associated virus (AAV) capsid requires a distinct approach compared to leveraging established serotypes. The process must integrate structural biology, receptor affinity quantification, and bespoke analytical development to build a robust data package for regulatory submissions. A successful program de-risks immunogenicity by understanding capsid structure and confirms tissue-specific targeting by correlating receptor distribution with vector performance. This ensures the final therapeutic candidate is not only potent but also manufacturable and well-characterized for a successful IND filing within an 18-24 month timeline.
Frequently Asked Questions
What are the primary CMC challenges when developing novel AAV capsids for gene therapy?
The main challenges involve establishing a scalable manufacturing process for a vector with unknown production characteristics, developing custom analytical methods to assess key quality attributes (CQAs) like potency and purity, and characterizing the unique immunogenicity profile of the engineered capsid to ensure a comprehensive risk assessment for IND-enabling toxicology studies.
How does capsid-receptor affinity impact the CMC and preclinical development of an engineered AAV vector?
Quantifying capsid-receptor affinity is a foundational analytical step. This data directly informs the mechanism of action and predicts in vivo biodistribution and potency. A robust CMC strategy uses these affinity metrics to establish product specifications and justify the therapeutic rationale, linking the engineered vector’s design directly to its intended biological function in nonclinical models.
For a novel AAV capsid, what defines a phase-appropriate analytical strategy for an IND submission?
A phase-appropriate strategy focuses on developing and qualifying assays that characterize product identity, purity, concentration, and potency. For a novel capsid, this includes bespoke methods to confirm structural integrity, quantify empty/full capsid ratios, and establish a relevant, cell-based potency assay that reflects the vector’s specific tropism and mechanism of action, all performed under GxP conditions where required.
Integrating Structural Biology into Early Vector Design
For next-generation therapeutics based on engineered AAV capsids, the CMC roadmap begins at the initial design stage. Unlike programs using clinically validated serotypes like AAV8 or AAV9, a novel capsid introduces unknowns that must be systematically addressed. The initial focus is on the structural characterization of the vector itself.
High-resolution structural analysis, such as X-ray crystallography, provides a foundational understanding of the capsid’s surface-exposed variable regions. This insight is directly applicable to de-risking development. As demonstrated with vectors like AAVrh32.33, identifying key structural differences allows for rational engineering to potentially evade pre-existing neutralizing antibodies in the patient population (PMID: 24704217). This structural data becomes a cornerstone of the CMC package, justifying the vector’s design and informing the immunogenicity risk assessment.
From Receptor Affinity to a Predictive Biodistribution Profile
An engineered capsid’s value lies in its ability to achieve targeted delivery and enhanced potency. A data-driven CMC strategy must quantitatively link the vector’s design to its biological performance. This is achieved by developing assays that measure the binding affinity between the novel capsid and its target cellular receptor.
-
Quantitative Affinity Assays: High-throughput methods are used to measure the binding kinetics, providing a key quality attribute (CQA) for the vector.
-
Receptor Distribution Mapping: Correlating vector affinity with the expression profile of the target receptor in specific tissues is necessary.
-
Predictive In Vivo Performance: This combined dataset allows for a more accurate prediction of tissue-specific targeting and potential non-target tissue biodistribution, as shown in models exploring BBB penetration (PMID: 37199615). This data is vital for designing informative IND-enabling toxicology studies.
Building a Robust, Phase-Appropriate Analytical Package
The analytical control strategy for a novel capsid must be purpose-built. Standard assays may require significant modification or replacement to accurately characterize a bio-engineered vector. Our approach, refined across thousands of research batches and collaborations with sponsors like our partners, focuses on creating a comprehensive analytical toolkit. For a deeper look at initiating these programs, our webinar on AAV project success covers these key factors.
The core team’s track record, which contributes to a 100% successful IND rate since 2019, is built on this principle of bespoke analytical development. While Franklin Biolabs was formally launched in 2024, this success reflects the deep institutional knowledge of our founding scientific leadership and principal scientists in preparing these complex data packages.
A successful scientific extension transitions this rigor from early discovery into a scalable manufacturing process. As one partner noted:
“The key people from UPenn Vector Core joined Franklin Biolabs and our collaboration transitioned without interruption… Franklin Biolabs provides the critical scientific and manufacturing expertise for our AAV-vector based gene therapy candidate development, and we hope to continue the collaboration for years to come.”
This continuity ensures that the foundational science established during vector engineering is seamlessly translated into a scalable process within our >100,000 sq ft facilities, ready for GxP-compliant production and IND submission.
This integrated approach connects early vector design with late-stage manufacturing and regulatory requirements, providing a clear path from concept to clinic. For more information on our broader capabilities, please see our main Vector | CMC | Analytics Services page.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.